Public

  1. Showing 77 results for:
  2. Funding
  3. Public
All Subjects

Long-term access and preservation infrastructure development for EOSC, including data quality aspects

Published by European Commission (EC)

CloudOpen Science

In the digital and data driven paradigm promoted by Open Science, data is at the core of the scientific process and its production grows at ever increasing rates. The volume of data currently is many-fold larger compared to just two years ago. In science there are many intermediate data objects being created through the phases of research activities and they are managed within the research data lifecycle in which curation and preservation are key elements to make accessible data that are interoperable and reusable. Costs and physical limitations of storage and service capacity lead to the difficult question of what is worth long term preserving narrowing the selection to data and other digital objects that will have long-term benefits to science and society.

Coordination to harmonise practices and standards within and across the different scientific fields and adequate infrastructures are necessary to implement the level of curation and preservation needed and to offer the related services that differ in practice and effort per discipline ant type of data.

View this resource Bookmark this resource

NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)

Published by NIH

Clinical TrialsRare diseasesSmall Business Innovation Research

The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies.

View this resource Bookmark this resource

Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required

Published by NIH

Clinical TrialRare diseasesUnmet Needs

The purpose of this funding opportunity announcement (FOA) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development.

View this resource Bookmark this resource

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)

Published by NIH

Pain ManagementScreening ToolsTherapies and Technologies

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

View this resource Bookmark this resource

Developing EU Methodological Frameworks for Clinical/Performance Evaluation and Post-market Clinical/Performance Follow-up of Medical Devices and In Vitro Diagnostic Medical Devices (IVDs)

Published by European Commission (EC)

ClinicMedical Device

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”.

View this resource Bookmark this resource

Bio-printing of Living Cells for Regenerative Medicine

Published by European Commission (EC)

Regenerative Medicine

Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the “process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function”. 3D-printing in general is considered an advanced manufacturing technique and 3D-printing of non-viable biomaterials to serve e.g. as scaffold for cell growth or as structure for medical devices is already broadly used.

However, bio-printing technology involving living cells is still in early stages of development, but has a huge potential for tissue engineering, drug testing and other biomedical applications. Tissue-specific functional 3D bio-printing is a new approach for transplantation applications in regenerative medicine, relying on the fabrication of tissues and organs with respect to the desired shape and function and their delivery and application in vivo. “In-situ bio-printing” known as printing cells and biomaterials directly onto or in a patient, or 4D bio-printing, which introduces a “time” variable that allows 3D printed materials to change shape or function when external stimulus is applied, are recent developments facing multiple additional challenges.

Despite some success of 3D bio-printing with thin tissue, thick tissue and complex organs remain a bottleneck because it is difficult to sufficiently mimic their metabolic needs, and the scientific knowledge about their intimate architecture and interplay with other tissues are not sufficiently elucidated. Next to these limitations are a lack of standardised manufacturing protocols and standardised bio-ink formulations with tuneable properties, unstable cellular behaviour, material biocompatibility and printability, etc. Taken together, 3D bio-printing is confronted with several challenges that currently hamper its large-scale deployment.

View this resource Bookmark this resource

Funding Open Call: A simple One-Step Application Process

Published by COST

COSTGrant

Participants are invited to submit COST Action proposals contributing to the scientific, technological, economic, cultural or societal knowledge advancement and development of Europe. Multi- and interdisciplinary proposals are encouraged.

View this resource Bookmark this resource

Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)

Published by NIH

BiomarkersClinical Trial ReadinessRare diseases

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

View this resource Bookmark this resource

NICHD Research Education Programs (R25 Clinical Trial Not Allowed)

Published by NIH

Educational ProgrammeResearch ExperienceSkill Development

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

View this resource Bookmark this resource

Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)

Published by NIH

Rare diseasesUnderstudied Proteins

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This FOA is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins associated with rare disease.

View this resource Bookmark this resource